EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906

Arvid Jungnik, Jorge Arrubla Martinez iD, Leona Plum-Mörschel iD, Christoph Kapitza iD, Daniela Lamers, Claus Thamer, Corinna Schölch, Michael Desch iD, Anita M Hennige

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.14948 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Arvid Jungnik und 8 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim Pharma GmbH, Biberach, Germany. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim España.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim To report two phase I studies of the novel subcutaneous glucagon‐like peptide‐1 receptor/glucagon receptor (GLP‐1R/GCGR) dual agonist BI 456906 versus placebo in healthy volunteers and people with overweight/obesity. Materials and Methods A phase Ia study (NCT03175211) investigated single rising doses (SRDs) of BI 456906 in 24 males with a body mass index (BMI) of 20–

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1Diabetes Mellitus, Type 2AdultMaleHumansHypoglycemic AgentsReceptors, GlucagonOverweightBlood GlucoseBody WeightObesityWeight LossDouble-Blind MethodGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

BI 456906dual agonismglucagon receptor agonistglucagon-like peptide-1 receptor agonistobesitypharmacodynamicspharmacokineticssafetytolerability

Substanzen

Glucagon-Like Peptide 1Hypoglycemic AgentsReceptors, GlucagonBlood GlucoseGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Boehringer Ingelheim Pharma GmbH, Biberach, Germany.
  • Profil Institute for Metabolic Research, Neuss, Germany.
  • Profil Mainz GmbH & Co. KG, Mainz, Germany.
  • Boehringer Ingelheim International GmbH, Biberach, Germany.

ORCID-Profile: Jorge Arrubla Martinez, Leona Plum-Mörschel, Christoph Kapitza, Michael Desch

Förderung

  • Boehringer Ingelheim España

Zitieren

APA

Jungnik, A., Arrubla Martinez, J., Plum-Mörschel, L., Kapitza, C., Lamers, D., Thamer, C., Schölch, C., Desch, M., & Hennige, A. M. (2023). Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14948

Vancouver

Jungnik A, Arrubla Martinez J, Plum-Mörschel L, Kapitza C, Lamers D, Thamer C, et al. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.14948

BibTeX
@article{Jungnik2023,
  author = {Jungnik, Arvid and Arrubla Martinez, Jorge and Plum-Mörschel, Leona and Kapitza, Christoph and Lamers, Daniela and Thamer, Claus and Schölch, Corinna and Desch, Michael and Hennige, Anita M},
  title = {Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.14948}
}
Kostenlos starten →